MiniVax, Inc., develops solutions for the treatment and prevention of opportunistic infections, specifically the indication Pneumocystis pneumonia (PCP). The company’s revenues are below $1 million and it raised thus far $110,000 out of a $1.5 million equity offering for which no placement agent has been hired.
MiniVax, Inc. is headquartered in New Orleans, LA and was founded in December 2010. MiniVax’s lead product candidate is a monoclonal antibody (PCP-Antibody) for the treatment of PCP. The company is led by Aniruddho Ray Chaudhuri (CEO and COB) and Martin Preuveneers (COO).